SM
NBIX icon

Sabby Management’s Neurocrine Biosciences NBIX Stock Holding History

Sabby Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,153
Closed -$4.46M – 289
2016
Q4 		$4.46M Sell
1,153
-61
-5% -$2.76K 0.26% 58
2016
Q3 		$6.15M Buy
1,214
+401
+49% +$20K 0.23% 65
2016
Q2 		$3.69M Buy
813
+448
+123% +$20.6K 0.19% 68
2016
Q1 		$1.44M Sell
365
-912
-71% -$36.2K 0.07% 129
2015
Q4 		$7.22M Sell
1,277
-126
-9% -$6.4K 0.4% 42
2015
Q3 		$5.58M Buy
1,403
+20
+1% +$967 0.23% 73
2015
Q2 		$6.61M Buy
1,383
+95
+7% +$4.03K 0.24% 78
2015
Q1 		$5.12M Sell
1,288
-305
-19% -$10.9K 0.21% 75
2014
Q4 		$3.56K Sell
1,593
-82
-5% -$1.55K 0.11% 87
2014
Q3 		$2.63K Buy
1,675
+348
+26% +$5.2K 0.1% 88
2014
Q2 		$1.97M Buy
1,327
+20
+2% +$282 0.08% 105
2014
Q1 		$2.1M Hold
1,307
– – 0.12% 102
2013
Q4 		$1.22M Buy
+1,307
New +$12.8K 0.08% 106
2013
Q3 		– Sell
-3,861
Closed -$5.17M – 214
2013
Q2 		$5.17M Buy
+3,861
New +$47.4K 0.34% 61

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sabby Management's NBIX Position: Q2 2016 in Review

Sabby Management sold out of Neurocrine Biosciences (NBIX) in Q2 2016, closing a stake of 70,000 shares — an estimated $3.22M sold.

Sabby Management first reported a position in NBIX in Q3 2013 and held it in 2 quarters. The position peaked at $2.77M in Q1 2016. 231 funds tracked by Wall St. Rank hold NBIX as of Q2 2016.

  • Sabby Management reported no remaining Neurocrine Biosciences position as of Q2 2016 after selling out during the quarter.
  • Sabby Management sold 70,000 Neurocrine Biosciences shares in Q2 2016, an estimated $3.22M.
  • Sabby Management first reported a position in Neurocrine Biosciences in Q3 2013 and held it in 2 quarters.
  • Sabby Management's Neurocrine Biosciences position peaked at $2.77M in Q1 2016.
  • 231 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2016.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.